The L-type channel antagonist isradipine is neuroprotective in a mouse model of Parkinson's disease
The motor symptoms of Parkinson's disease (PD) are due to the progressive loss of dopamine (DA) neurons in substantia nigra pars compacta (SNc). Nothing is known to slow the progression of the disease, making the identification of potential neuroprotective agents of great clinical importance. P...
Main Authors: | E. Ilijic, J.N. Guzman, D.J. Surmeier |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2011-08-01
|
Series: | Neurobiology of Disease |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S0969996111001240 |
Similar Items
-
Effects of Postnatal Enriched Environment in a Model of Parkinson’s Disease in Adult Rats
by: Adel Jungling, et al.
Published: (2017-02-01) -
Bursting activity of substantia nigra pars reticulata neurons in mouse parkinsonism in awake and anesthetized states
by: C.J. Lobb, et al.
Published: (2015-03-01) -
Formulation and Characterization of Isradipine as Oral Nanoemulsion
by: Noor A. sadoon, et al.
Published: (2020-06-01) -
Spectrophotometric determination of nicradipine and isradipine in pharmaceutical formulations
by: S. M. Al-Ghannam, et al.
Published: (2009-05-01) -
Isradipine – a calcium channel blocker – does not potentiate chloroquine antiplasmodial activity against Plasmodium falciparum
by: Randrianarivelojosia M., et al.
Published: (2005-06-01)